-
1.发明授权公开(公告)号：US11999704B1
公开(公告)日：2024-06-04
申请号：US18430527
申请日：2024-02-01
发明人： Mai Mostafa Khalaf Ali , Hany Mohamed Abd El-Lateef Ahmed , Antar Ahmed Abdelhamid Ahmed , Amer A. Amer
IPC分类号： C07D233/80 , A61P31/04 , A61P31/10
CPC分类号： C07D233/80 , A61P31/04 , A61P31/10
摘要： A 1-(2-hydroxybenzylideneamino)-5-phenylimidazolidine-2,4-dione compound, its synthesis, and its use as an antimicrobial agent.
-
2.发明授权公开(公告)号：US11905254B1
公开(公告)日：2024-02-20
申请号：US18488967
申请日：2023-10-17
发明人： Hany Mohamed Abd El-Lateef Ahmed , Mai Mostafa Khalaf Ali , Antar Ahmed Abdelhamid Ahmed , Amer A. Amer
IPC分类号： C07D233/80 , A61P31/10 , A61P31/04
CPC分类号： C07D233/80 , A61P31/04 , A61P31/10
摘要： A 1-(3-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione compound, its synthesis, and its use as an antimicrobial agent.
-
公开(公告)号：US11014924B2
公开(公告)日：2021-05-25
申请号：US16462171
申请日：2017-11-21
发明人： Mark Spyvee , Robert D. Ladner
IPC分类号： C07D471/10 , C07D207/38 , C07D209/48 , A61P35/00 , C07D233/76 , C07D233/80 , C07D249/12 , C07D263/44 , C07D471/04 , C07D487/04 , C07D487/10
摘要： Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
-
公开(公告)号：US10899718B2
公开(公告)日：2021-01-26
申请号：US15692234
申请日：2017-08-31
发明人： Steven Luo
摘要： A method for preparing a functionalized polymer, the method comprising the steps of (i) polymerizing monomer to form a reactive polymer; and (ii) reacting the reactive polymer with an N-protected hydantoin compound.
-
公开(公告)号：US20210000846A1
公开(公告)日：2021-01-07
申请号：US17028416
申请日：2020-09-22
申请人： Allergan, Inc.
IPC分类号： A61K31/683 , C07F9/40 , C07C235/82 , C07C275/42 , C07D217/24 , C07D223/10 , C07D233/80 , C07D235/02 , C07D257/04 , C07D261/12 , C07D401/06 , C07D405/06 , C07D405/14 , C07D409/06 , A61P17/12 , A61P17/02 , A61P35/00 , A61P17/18 , A61P17/10 , A61P17/04 , A61P17/14 , A61P17/06 , A61P17/16 , A61K31/17 , A61K31/196 , A61K31/4166 , A61K31/42 , A61K31/662 , A61P17/08 , A61K9/00 , A61K31/167 , A61K31/192 , A61K31/4045 , A61K31/41 , A61K31/4174 , A61K31/4178 , A61K31/4184 , A61K31/472 , A61K31/4725 , A61K31/55
摘要： The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
-
公开(公告)号：US09789090B2
公开(公告)日：2017-10-17
申请号：US15144124
申请日：2016-05-02
IPC分类号： A61K9/14 , A61K9/00 , A61K31/415 , A61K31/4178 , A61K9/127 , A61K47/10 , A61K47/18 , A61K9/10 , A61K9/16 , A61K31/4166 , C07D233/80
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
-
公开(公告)号：US09567302B2
公开(公告)日：2017-02-14
申请号：US14383076
申请日：2013-03-15
发明人： Justin S. Cisar , Cheryl A. Grice , Todd K. Jones , Dong-Hui Wang , Olivia Weber , Benjamin F. Cravatt , Micah J. Niphakis , Armand Cognetta , Jae Won Chang
IPC分类号： C07D207/46 , C07D401/12 , C07D405/14 , C07D413/12 , C07D413/14 , A61K31/496 , A61K31/454 , C07D403/12 , C07D401/14 , C07D491/08 , C07D233/80 , C07D403/14 , C07D417/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/08 , C07D209/48
CPC分类号： C07D207/46 , C07D209/48 , C07D233/80 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/08 , C07D491/107 , C07D498/08
摘要： Provided herein are carbamate compounds which may be useful in the treatment of for example, pain, solid tumors and/or obesity.
摘要翻译： 本文提供了可用于治疗例如疼痛，实体瘤和/或肥胖症的氨基甲酸酯化合物。
-
公开(公告)号：US08685460B2
公开(公告)日：2014-04-01
申请号：US13353478
申请日：2012-01-19
IPC分类号： A61K9/16 , A61K31/415 , A61K9/00 , A61K9/10 , A61K31/4166 , C07D233/80
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译： 提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。 一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。 丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术 涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。
-
公开(公告)号：US20090312382A1
公开(公告)日：2009-12-17
申请号：US12477943
申请日：2009-06-04
IPC分类号： A61K31/415 , C07D233/80
CPC分类号： C07D233/38 , C07D211/96 , C07D241/04 , C07D241/08 , C07D401/10 , C07D413/12
摘要： The invention is concerned with novel imidazolidine derivatives of formula (I) wherein R1 to R3, A, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.
摘要翻译： 本发明涉及式（I）的新咪唑烷衍生物，其中R 1至R 3，A，D和E如说明书和权利要求书中所定义，以及其生理学上可接受的盐和酯。 这些化合物与LXRα和LXRβ结合，可用作药物。
-
10.发明申请Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 失效制备1型11β-羟基类固醇脱氢酶的C-5-取代的杂环抑制剂的催化方法公开(公告)号：US20070117985A1
公开(公告)日：2007-05-24
申请号：US11590922
申请日：2006-11-01
申请人： Emilio Bunel , Anil Guram , Qingyian Liu
发明人： Emilio Bunel , Anil Guram , Qingyian Liu
IPC分类号： C07D263/00 , C07D233/80 , C07D233/38
CPC分类号： C07D277/54 , C07D277/42
摘要： The invention provides a process for preparing 11 β-hydroxy steroid dehydrogenase type 1 inhibitors of formula 2 via a catalyzed reaction between a compound of formula 1 and a compound of formula R2LG in the presence of base: where R1, R2, X, Y, and LG are described in the specification. Exemplary catalysts contain palladium and one or more phosphine ligands. The process can be performed in a stereoselective manner to give enantiomerically enriched products.
摘要翻译： 本发明提供了在碱存在下通过式1化合物与式R 2 LG化合物之间的催化反应来制备式II的11β-羟基类固醇脱氢酶1型抑制剂的方法： 其中R 1，R 2，X，Y和LG在说明书中描述。 示例性催化剂含有钯和一种或多种膦配体。 该方法可以以立体选择性方式进行，得到对映异构体富集的产物。
-
-
-
-
-
-
-
-
-
搜索结果
179 条记录 (耗时 0.025 秒)
